Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Assets (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Non-Current Assets for 7 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 84.97% to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, down 84.97% year-over-year, with the annual reading at $8.4 million for FY2025, 84.97% down from the prior year.
  • Non-Current Assets hit $8.4 million in Q4 2025 for Immunocore Holdings, down from $79.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $80.1 million in Q2 2025 to a low of $8.4 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $61.4 million across 5 years, with a median of $66.5 million in 2024.
  • Biggest YoY gain for Non-Current Assets was 20.42% in 2025; the steepest drop was 84.97% in 2025.
  • Year by year, Non-Current Assets stood at $52.6 million in 2021, then decreased by 2.76% to $51.2 million in 2022, then rose by 8.24% to $55.4 million in 2023, then rose by 0.9% to $55.9 million in 2024, then plummeted by 84.97% to $8.4 million in 2025.
  • Business Quant data shows Non-Current Assets for IMCR at $8.4 million in Q4 2025, $79.7 million in Q3 2025, and $80.1 million in Q2 2025.